Table 1 Clinical and laboratory characteristics of patients and controls.
From: Localization of lipopolysaccharide from Escherichia Coli into human atherosclerotic plaque
Controls (n = 15) | Patients (n = 10) | p | |
|---|---|---|---|
Age | 70.7 ± 6.0 | 73.1 ± 8.9 | 0.433 |
Women (%) | 26.7 | 20.0 | 0.702 |
Hypertension (%) | 100.0 | 100.0 | — |
Dyslipidaemia (%) | 90 | 90 | — |
Diabetes (%) | 53.3 | 30.0 | 0.414 |
BMI (Kg/m2) | 28.2 ± 2.7 | 27.1 ± 2.6 | 0.458 |
ACE/ARBs (%) | 86.7 | 70.0 | 0.358 |
Β-blockers (%) | 33.3 | 10.0 | 0.345 |
Antiplatelet drugs (%) | 100.0 | 100.0 | — |
Statins (%) | 100.0 | 90.0 | 0.400 |
Serum LPS (pg/ml) | 43.5 ± 11.9 | 79.0 ± 10.7 | <0.001 |
Serum zonulin (ng/ml) | 2.2 ± 1.1 | 4.5 ± 0.7 | <0.001 |
